Table 2. The influence of CYP 2D6 genetic factors and breakdown of demographics.
Poor Metabolizer(N = 11) | Intermediate Metabolizer(N = 70) | Extensive Metabolizer (N = 105) | Ultra-rapid Metabolizer (N = 6) | |
Total Codeine Dose (mg/kg/day) | 1.4±0.6 | 1.1±0.4 | 1.2±0.5 | 1.2±0.3 |
Total No. days on codeine | 2 (1–3) | 2 (1–9) | 2 (1–9) | 2 (1–3) |
Maternal Age (years) | 34.5±5.5 | 32.9±5.7 | 32.6±5.51 | 32.0±6.8 |
No. times breastfed in 24hours | 9 (7–10) | 9 (6–13) | 8.75 (3–11.5) | 9 (7–13) |
Baby GA (weeks) | 39.3±1.4 | 39.0±1.2 | 38.5±1.3 | 38.8±0.4 |
Baby weight (grams) | 3517.5±513.4 | 3379.4±510.8 | 3421.3±519.5 | 3199±321.8 |
No. reported infant ADRs (%) | 0 | 3 (4%) | 2 (2%) | 0 |
No. reported maternal ADRs (%) | 1 (9%) | 7 (10%) | 7 (6%) | 0 |
Patient characteristics and reported outcomes broken down by CYP2D6 phenotype, where a poor metabolizer has a CYP2D6 activity score of 0, intermediate a score between 0.5–1.0, extensive a score between 1.5–2.0 and ultra-rapid a score of 2.5 or higher. Data are presented as mean ± standard deviation, and median (range) for nonparametric data.